Secretome Therapeutics

Secretome Therapeutics is a clinical-stage biopharmaceutical company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs) to treat underserved diseases. Its lead candidate, STM-01, is in clinical development for adult and pediatric heart failure; its pipeline also includes secretome-based therapeutics for neurodegenerative and dermatological conditions. The company seeks to address unmet medical needs through regenerative cell-based products and related secreted biological factors.